Mitogen Activated Protein Kinase 1 - Pipeline Review, H2 2019
Mitogen Activated Protein Kinase 1 - Pipeline Review, H2 2019
SUMMARY
According to the recently published report 'Mitogen Activated Protein Kinase 1 - Pipeline Review, H2 2019'; Mitogen Activated Protein Kinase 1 (ERT1 or MAP Kinase Isoform p42 or Extracellular Signal Regulated Kinase 2 or Mitogen Activated Protein Kinase 2 or MAPK1 or EC 2.7.11.24) pipeline Target constitutes close to 14 molecules.
Mitogen Activated Protein Kinase 1 (ERT1 or MAP Kinase Isoform p42 or Extracellular Signal Regulated Kinase 2 or Mitogen Activated Protein Kinase 2 or MAPK1 or EC 2.7.11.24) - Mitogen-activated protein kinase 1 is an enzyme encoded by the MAPK1 gene. It is involved variety of cellular processes such as proliferation, differentiation, transcription regulation and development. The activation of this kinase requires its phosphorylation by upstream kinases. Upon activation, they translocates to the nucleus of the stimulated cells, where it phosphorylates nuclear targets. It acts as a transcriptional repressor. It plays an important role in the spindle assembly checkpoint.
The report 'Mitogen Activated Protein Kinase 1 - Pipeline Review, H2 2019' outlays comprehensive information on the Mitogen Activated Protein Kinase 1 (ERT1 or MAP Kinase Isoform p42 or Extracellular Signal Regulated Kinase 2 or Mitogen Activated Protein Kinase 2 or MAPK1 or EC 2.7.11.24) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.
It also reviews key players involved in Mitogen Activated Protein Kinase 1 (ERT1 or MAP Kinase Isoform p42 or Extracellular Signal Regulated Kinase 2 or Mitogen Activated Protein Kinase 2 or MAPK1 or EC 2.7.11.24) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 3, 6, 3 and 2 respectively. Report covers products from therapy areas Oncology, Immunology and Musculoskeletal Disorders which include indications Non-Small Cell Lung Cancer, Metastatic Colorectal Cancer, Metastatic Melanoma, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, Esophageal Cancer, Melanoma, Solid Tumor, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Adenocarcinoma, Bile Duct Cancer (Cholangiocarcinoma), Breast Cancer, Chronic Lymphocytic Leukemia (CLL), Gastric Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Hepatocellular Carcinoma, Inflammation, Knee Osteoarthritis, Lung Cancer, Mantle Cell Lymphoma, Marginal Zone B-cell Lymphoma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Pancreatic Cancer, Metastatic Uveal Melanoma, Myelodysplastic Syndrome, Pancreatic Cancer, Psoriasis, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Renal Cell Carcinoma and Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma).
SCOPE
SUMMARY
According to the recently published report 'Mitogen Activated Protein Kinase 1 - Pipeline Review, H2 2019'; Mitogen Activated Protein Kinase 1 (ERT1 or MAP Kinase Isoform p42 or Extracellular Signal Regulated Kinase 2 or Mitogen Activated Protein Kinase 2 or MAPK1 or EC 2.7.11.24) pipeline Target constitutes close to 14 molecules.
Mitogen Activated Protein Kinase 1 (ERT1 or MAP Kinase Isoform p42 or Extracellular Signal Regulated Kinase 2 or Mitogen Activated Protein Kinase 2 or MAPK1 or EC 2.7.11.24) - Mitogen-activated protein kinase 1 is an enzyme encoded by the MAPK1 gene. It is involved variety of cellular processes such as proliferation, differentiation, transcription regulation and development. The activation of this kinase requires its phosphorylation by upstream kinases. Upon activation, they translocates to the nucleus of the stimulated cells, where it phosphorylates nuclear targets. It acts as a transcriptional repressor. It plays an important role in the spindle assembly checkpoint.
The report 'Mitogen Activated Protein Kinase 1 - Pipeline Review, H2 2019' outlays comprehensive information on the Mitogen Activated Protein Kinase 1 (ERT1 or MAP Kinase Isoform p42 or Extracellular Signal Regulated Kinase 2 or Mitogen Activated Protein Kinase 2 or MAPK1 or EC 2.7.11.24) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.
It also reviews key players involved in Mitogen Activated Protein Kinase 1 (ERT1 or MAP Kinase Isoform p42 or Extracellular Signal Regulated Kinase 2 or Mitogen Activated Protein Kinase 2 or MAPK1 or EC 2.7.11.24) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 3, 6, 3 and 2 respectively. Report covers products from therapy areas Oncology, Immunology and Musculoskeletal Disorders which include indications Non-Small Cell Lung Cancer, Metastatic Colorectal Cancer, Metastatic Melanoma, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, Esophageal Cancer, Melanoma, Solid Tumor, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Adenocarcinoma, Bile Duct Cancer (Cholangiocarcinoma), Breast Cancer, Chronic Lymphocytic Leukemia (CLL), Gastric Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Hepatocellular Carcinoma, Inflammation, Knee Osteoarthritis, Lung Cancer, Mantle Cell Lymphoma, Marginal Zone B-cell Lymphoma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Pancreatic Cancer, Metastatic Uveal Melanoma, Myelodysplastic Syndrome, Pancreatic Cancer, Psoriasis, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Renal Cell Carcinoma and Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma).
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Mitogen Activated Protein Kinase 1 (ERT1 or MAP Kinase Isoform p42 or Extracellular Signal Regulated Kinase 2 or Mitogen Activated Protein Kinase 2 or MAPK1 or EC 2.7.11.24)
- The report reviews Mitogen Activated Protein Kinase 1 (ERT1 or MAP Kinase Isoform p42 or Extracellular Signal Regulated Kinase 2 or Mitogen Activated Protein Kinase 2 or MAPK1 or EC 2.7.11.24) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Mitogen Activated Protein Kinase 1 (ERT1 or MAP Kinase Isoform p42 or Extracellular Signal Regulated Kinase 2 or Mitogen Activated Protein Kinase 2 or MAPK1 or EC 2.7.11.24) targeted therapeutics and enlists all their major and minor projects
- The report assesses Mitogen Activated Protein Kinase 1 (ERT1 or MAP Kinase Isoform p42 or Extracellular Signal Regulated Kinase 2 or Mitogen Activated Protein Kinase 2 or MAPK1 or EC 2.7.11.24) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Mitogen Activated Protein Kinase 1 (ERT1 or MAP Kinase Isoform p42 or Extracellular Signal Regulated Kinase 2 or Mitogen Activated Protein Kinase 2 or MAPK1 or EC 2.7.11.24) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Mitogen Activated Protein Kinase 1 (ERT1 or MAP Kinase Isoform p42 or Extracellular Signal Regulated Kinase 2 or Mitogen Activated Protein Kinase 2 or MAPK1 or EC 2.7.11.24)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Mitogen Activated Protein Kinase 1 (ERT1 or MAP Kinase Isoform p42 or Extracellular Signal Regulated Kinase 2 or Mitogen Activated Protein Kinase 2 or MAPK1 or EC 2.7.11.24) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Mitogen Activated Protein Kinase 1 (ERT1 or MAP Kinase Isoform p42 or Extracellular Signal Regulated Kinase 2 or Mitogen Activated Protein Kinase 2 or MAPK1 or EC 2.7.11.24) - Overview
Mitogen Activated Protein Kinase 1 (ERT1 or MAP Kinase Isoform p42 or Extracellular Signal Regulated Kinase 2 or Mitogen Activated Protein Kinase 2 or MAPK1 or EC 2.7.11.24) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Mitogen Activated Protein Kinase 1 (ERT1 or MAP Kinase Isoform p42 or Extracellular Signal Regulated Kinase 2 or Mitogen Activated Protein Kinase 2 or MAPK1 or EC 2.7.11.24) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Mitogen Activated Protein Kinase 1 (ERT1 or MAP Kinase Isoform p42 or Extracellular Signal Regulated Kinase 2 or Mitogen Activated Protein Kinase 2 or MAPK1 or EC 2.7.11.24) - Companies Involved in Therapeutics Development
Antengene Corp
Asana BioSciences LLC
Astex Pharmaceuticals Inc
BioMed Valley Discoveries Inc
Bristol-Myers Squibb Co
Eli Lilly and Co
Hutchison MediPharma Ltd
Kalyra Pharmaceuticals Inc
Kura Oncology Inc
Merck & Co Inc
Merck KGaA
Prous Institute for Biomedical Research SA
Shanghai Green Valley Pharmaceutical Co Ltd
Mitogen Activated Protein Kinase 1 (ERT1 or MAP Kinase Isoform p42 or Extracellular Signal Regulated Kinase 2 or Mitogen Activated Protein Kinase 2 or MAPK1 or EC 2.7.11.24) - Drug Profiles
ASN-007 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ASTX-029 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ATG-017 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CC-99677 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JRP-890 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JSI-287 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KO-947 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LY-3214996 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MK-8353 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit MAPK1 (ERK) for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit ERK1 and ERK2 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit ERK1 and ERK2 for Pancreatic Ductal Adenocarcinoma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sprifermin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ulixertinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Mitogen Activated Protein Kinase 1 (ERT1 or MAP Kinase Isoform p42 or Extracellular Signal Regulated Kinase 2 or Mitogen Activated Protein Kinase 2 or MAPK1 or EC 2.7.11.24) - Dormant Products
Mitogen Activated Protein Kinase 1 (ERT1 or MAP Kinase Isoform p42 or Extracellular Signal Regulated Kinase 2 or Mitogen Activated Protein Kinase 2 or MAPK1 or EC 2.7.11.24) - Discontinued Products
Mitogen Activated Protein Kinase 1 (ERT1 or MAP Kinase Isoform p42 or Extracellular Signal Regulated Kinase 2 or Mitogen Activated Protein Kinase 2 or MAPK1 or EC 2.7.11.24) - Product Development Milestones
Featured News & Press Releases
Oct 24, 2019: Asana BioSciences to present phase 1 clinical safety and efficacy data of oral, once-weekly, ASN007, a novel ERK 1/2 inhibitor, at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
Oct 08, 2019: EMD Serono Announces JAMA Publication of Phase II Results of Sprifermin for Osteoarthritis Structure Modification
May 15, 2019: Eli Lilly presents update on ERK inhibitor, LY3214996 at ASCO 2019
Apr 17, 2018: Merck to Present on Sprifermin at OARSI 2018 World Congress
Apr 10, 2018: Asana BioSciences Announces Presentations of ASN007 (ERK1/2 inhibitor) at the American Association for Cancer Research Annual Meeting
Apr 09, 2018: Kura Oncology Presents Poster on KO-947 at AACR Annual Meeting 2018
Feb 22, 2018: Phase I Clinical Trial Shows Promise as Investigational Drug for Melanoma
Jan 03, 2018: Asana BioSciences Announces Acceptance of IND Application for Its Oral ERK1/2 Inhibitor
Dec 15, 2017: First-in-class ERK1/2 Inhibitor Safe, Shows Early Efficacy in Patients With Advanced Solid Tumors
Nov 04, 2017: Merck KGaA, Darmstadt, Germany Presents Late Breaking Clinical Data from Phase II Trial of Sprifermin for Osteoarthritis Disease Modification
Oct 24, 2017: Asana BioSciences to Present Update On Lead Molecule ASN-007 at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Oct 20, 2017: Merck Presents New Data on Sprifermin at 2017 ACR/ARHP Annual Meeting
Oct 03, 2017: First-in-class ERK inhibitor ulixertinib (BVD-523) shows promise in preclinical cancer models
Jun 21, 2017: NovellusDx Announced the Completion of the First Phase of an In-vitro Study of BioMed Valley Discoveries' BVD523
May 26, 2017: BioMed Valley Discoveries announces presentation of early clinical activity of first-in-class cancer therapy ulixertinib at 2017 ASCO annual meeting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Mitogen Activated Protein Kinase 1 (ERT1 or MAP Kinase Isoform p42 or Extracellular Signal Regulated Kinase 2 or Mitogen Activated Protein Kinase 2 or MAPK1 or EC 2.7.11.24) - Overview
Mitogen Activated Protein Kinase 1 (ERT1 or MAP Kinase Isoform p42 or Extracellular Signal Regulated Kinase 2 or Mitogen Activated Protein Kinase 2 or MAPK1 or EC 2.7.11.24) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Mitogen Activated Protein Kinase 1 (ERT1 or MAP Kinase Isoform p42 or Extracellular Signal Regulated Kinase 2 or Mitogen Activated Protein Kinase 2 or MAPK1 or EC 2.7.11.24) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Mitogen Activated Protein Kinase 1 (ERT1 or MAP Kinase Isoform p42 or Extracellular Signal Regulated Kinase 2 or Mitogen Activated Protein Kinase 2 or MAPK1 or EC 2.7.11.24) - Companies Involved in Therapeutics Development
Antengene Corp
Asana BioSciences LLC
Astex Pharmaceuticals Inc
BioMed Valley Discoveries Inc
Bristol-Myers Squibb Co
Eli Lilly and Co
Hutchison MediPharma Ltd
Kalyra Pharmaceuticals Inc
Kura Oncology Inc
Merck & Co Inc
Merck KGaA
Prous Institute for Biomedical Research SA
Shanghai Green Valley Pharmaceutical Co Ltd
Mitogen Activated Protein Kinase 1 (ERT1 or MAP Kinase Isoform p42 or Extracellular Signal Regulated Kinase 2 or Mitogen Activated Protein Kinase 2 or MAPK1 or EC 2.7.11.24) - Drug Profiles
ASN-007 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ASTX-029 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ATG-017 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CC-99677 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JRP-890 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JSI-287 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KO-947 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LY-3214996 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MK-8353 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit MAPK1 (ERK) for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit ERK1 and ERK2 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit ERK1 and ERK2 for Pancreatic Ductal Adenocarcinoma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sprifermin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ulixertinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Mitogen Activated Protein Kinase 1 (ERT1 or MAP Kinase Isoform p42 or Extracellular Signal Regulated Kinase 2 or Mitogen Activated Protein Kinase 2 or MAPK1 or EC 2.7.11.24) - Dormant Products
Mitogen Activated Protein Kinase 1 (ERT1 or MAP Kinase Isoform p42 or Extracellular Signal Regulated Kinase 2 or Mitogen Activated Protein Kinase 2 or MAPK1 or EC 2.7.11.24) - Discontinued Products
Mitogen Activated Protein Kinase 1 (ERT1 or MAP Kinase Isoform p42 or Extracellular Signal Regulated Kinase 2 or Mitogen Activated Protein Kinase 2 or MAPK1 or EC 2.7.11.24) - Product Development Milestones
Featured News & Press Releases
Oct 24, 2019: Asana BioSciences to present phase 1 clinical safety and efficacy data of oral, once-weekly, ASN007, a novel ERK 1/2 inhibitor, at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
Oct 08, 2019: EMD Serono Announces JAMA Publication of Phase II Results of Sprifermin for Osteoarthritis Structure Modification
May 15, 2019: Eli Lilly presents update on ERK inhibitor, LY3214996 at ASCO 2019
Apr 17, 2018: Merck to Present on Sprifermin at OARSI 2018 World Congress
Apr 10, 2018: Asana BioSciences Announces Presentations of ASN007 (ERK1/2 inhibitor) at the American Association for Cancer Research Annual Meeting
Apr 09, 2018: Kura Oncology Presents Poster on KO-947 at AACR Annual Meeting 2018
Feb 22, 2018: Phase I Clinical Trial Shows Promise as Investigational Drug for Melanoma
Jan 03, 2018: Asana BioSciences Announces Acceptance of IND Application for Its Oral ERK1/2 Inhibitor
Dec 15, 2017: First-in-class ERK1/2 Inhibitor Safe, Shows Early Efficacy in Patients With Advanced Solid Tumors
Nov 04, 2017: Merck KGaA, Darmstadt, Germany Presents Late Breaking Clinical Data from Phase II Trial of Sprifermin for Osteoarthritis Disease Modification
Oct 24, 2017: Asana BioSciences to Present Update On Lead Molecule ASN-007 at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Oct 20, 2017: Merck Presents New Data on Sprifermin at 2017 ACR/ARHP Annual Meeting
Oct 03, 2017: First-in-class ERK inhibitor ulixertinib (BVD-523) shows promise in preclinical cancer models
Jun 21, 2017: NovellusDx Announced the Completion of the First Phase of an In-vitro Study of BioMed Valley Discoveries' BVD523
May 26, 2017: BioMed Valley Discoveries announces presentation of early clinical activity of first-in-class cancer therapy ulixertinib at 2017 ASCO annual meeting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Antengene Corp, H2 2019
Pipeline by Asana BioSciences LLC, H2 2019
Pipeline by Astex Pharmaceuticals Inc, H2 2019
Pipeline by BioMed Valley Discoveries Inc, H2 2019
Pipeline by Bristol-Myers Squibb Co, H2 2019
Pipeline by Eli Lilly and Co, H2 2019
Pipeline by Hutchison MediPharma Ltd, H2 2019
Pipeline by Kalyra Pharmaceuticals Inc, H2 2019
Pipeline by Kura Oncology Inc, H2 2019
Pipeline by Merck & Co Inc, H2 2019
Pipeline by Merck KGaA, H2 2019
Pipeline by Prous Institute for Biomedical Research SA, H2 2019
Pipeline by Shanghai Green Valley Pharmaceutical Co Ltd, H2 2019
Dormant Projects, H2 2019
Discontinued Products, H2 2019
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Antengene Corp, H2 2019
Pipeline by Asana BioSciences LLC, H2 2019
Pipeline by Astex Pharmaceuticals Inc, H2 2019
Pipeline by BioMed Valley Discoveries Inc, H2 2019
Pipeline by Bristol-Myers Squibb Co, H2 2019
Pipeline by Eli Lilly and Co, H2 2019
Pipeline by Hutchison MediPharma Ltd, H2 2019
Pipeline by Kalyra Pharmaceuticals Inc, H2 2019
Pipeline by Kura Oncology Inc, H2 2019
Pipeline by Merck & Co Inc, H2 2019
Pipeline by Merck KGaA, H2 2019
Pipeline by Prous Institute for Biomedical Research SA, H2 2019
Pipeline by Shanghai Green Valley Pharmaceutical Co Ltd, H2 2019
Dormant Projects, H2 2019
Discontinued Products, H2 2019
LIST OF FIGURES
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019
COMPANIES MENTIONED
Antengene Corp
Asana BioSciences LLC
Astex Pharmaceuticals Inc
BioMed Valley Discoveries Inc
Bristol-Myers Squibb Co
Eli Lilly and Co
Hutchison MediPharma Ltd
Kalyra Pharmaceuticals Inc
Kura Oncology Inc
Merck & Co Inc
Merck KGaA
Prous Institute for Biomedical Research SA
Shanghai Green Valley Pharmaceutical Co Ltd
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019
COMPANIES MENTIONED
Antengene Corp
Asana BioSciences LLC
Astex Pharmaceuticals Inc
BioMed Valley Discoveries Inc
Bristol-Myers Squibb Co
Eli Lilly and Co
Hutchison MediPharma Ltd
Kalyra Pharmaceuticals Inc
Kura Oncology Inc
Merck & Co Inc
Merck KGaA
Prous Institute for Biomedical Research SA
Shanghai Green Valley Pharmaceutical Co Ltd
